Mounjaro

Mounjaro reduces cardiovascular risk through dual GIP/GLP-1 receptor action, lowering inflammation and improving metabolic markers beyond weight loss

Mounjaro and antidepressants can be combined safely under medical supervision, though serotonin-affecting medications require closer monitoring for

Mounjaro (tirzepatide) treats obesity through dual GIP/GLP-1 receptor activation, delivering 15–22% body weight reduction. How it works, who qualifies,

Mounjaro shows 59% NASH resolution vs 17% placebo in clinical trials — effects extend beyond weight loss through direct hepatic GLP-1 receptor activation.

Mounjaro targets prediabetes by activating GIP and GLP-1 receptors to improve insulin sensitivity and lower A1C below diagnostic thresholds.

Mounjaro shows 59% NASH resolution vs 17% placebo in clinical trials, with significant hepatic fat reduction beyond weight loss alone in NAFLD patients.

If you are getting ready to stop Mounjaro, one of the first decisions that comes up is whether to step down the dose gradually…

Mounjaro tiredness gets glossed over in the prescribing information, which lists fatigue at roughly 4 to 6 percent across the SURPASS trial program.

Six-month tirzepatide weight loss averages roughly 12 to 18 percent of starting body weight at the higher maintenance doses (10 to 15 mg weekly).